We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Researchers in the Chapman Group have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.
Congratulation to Professor de Bruijn, who has been awarded funding from the UKRI Medical Research Council to investigate how the first blood stem cells formed in the embryo acquire their exceptional regenerative potential, with the aim of informing future stem cell therapies.
University of Oxford researchers have found that how fat accumulates in the body is just as important for identifying different health risks as a person’s overall weight.
Researchers in the Chapman Group have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.
Congratulation to Professor de Bruijn, who has been awarded funding from the UKRI Medical Research Council to investigate how the first blood stem cells formed in the embryo acquire their exceptional regenerative potential, with the aim of informing future stem cell therapies.
University of Oxford researchers have found that how fat accumulates in the body is just as important for identifying different health risks as a person’s overall weight.